A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
Updated: Apr 26, 2022
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
Establish the MTD of Lintuzumab-Ac225 as monotherapy
Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR)
Confirm the safety profile of the treatment regimen
Estimate progression-free survival (PFS) and overall survival
Sponsor:
Actinium Pharmaceuticals
Official Title: A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
First Posted : December 20, 2016
Actinium Ac 225 Lintuzumab (Code C82414)
225Ac-HuM195
Actinium (225Ac) Lintuzumab Satetraxetan
Actinium Ac 225 Lintuzumab
Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195
LINTUZUMAB SATETRAXETAN AC-225
SGN-33 AC-225
Locations
United States, California
United States, Kansas
United States, New York
United States, Texas
United States, Wisconsin